Loading…
Coherus Oncology, Inc. is projected to rise to $1.77 by 2027, a +7% move from its current price of $1.66. CHRS is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.60 | $1.66 | $1.72 | +0.02% |
| May 30 | $1.58 | $1.66 | $1.75 | +0.03% |
| May 31 | $1.56 | $1.66 | $1.77 | +0.05% |
| Jun 1 | $1.55 | $1.66 | $1.79 | +0.07% |
| Jun 2 | $1.53 | $1.66 | $1.80 | +0.08% |
| Jun 3 | $1.52 | $1.66 | $1.82 | +0.10% |
| Jun 4 | $1.51 | $1.66 | $1.83 | +0.11% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.51 | $1.66 | $1.83 | +0.11% |
| Week 2 | $1.45 | $1.66 | $1.90 | +0.23% |
| Week 3 | $1.41 | $1.67 | $1.97 | +0.34% |
| Week 4 | $1.38 | $1.67 | $2.02 | +0.46% |
| Week 5 | $1.35 | $1.67 | $2.07 | +0.57% |
| Week 6 | $1.32 | $1.67 | $2.11 | +0.69% |
| Week 7 | $1.30 | $1.67 | $2.15 | +0.80% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Coherus Oncology, Inc. is a biopharmaceutical company that researches, develops, and commercializes immunotherapies to treat cancer in the United States.
The company develops UDENYCA, a biosimilar to Neulasta, LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor, and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin IL-27. It is also developing CHS-114, an investigational human afucosylated IgG1 monoclonal antibody targeting a chemokine receptor highly expressed on Treg cells in the tumor microenvironment for head and neck squamous cell carcinoma. Coherus Oncology maintains collaboration and licensing arrangements with multiple partners, including Junshi Biosciences for toripalimab; Surface and Adimab LLC; Bioeq AG and Genentech, Inc.
and Surface and Vaccinex, Inc.; and an out-licensing agreement with Novartis Institutes for Biomedical Research and GlaxoSmithKline Intellectual Property No. 4 Limited.
The company was formerly known as Coherus BioSciences, Inc. and changed its name to Coherus Oncology, Inc. in May 2025. It was incorporated in 2010 and is based in Redwood City, California.
Coherus Oncology, Inc. (CHRS) trades around $1.61 per share with a market capitalization of $248.34M and a market ranking of 3674. The current price position sits within a broader, choppy trading profile as indicated by its near-term technicals.
Forecasts show a path of growth over the next several years. The 2026 forecast is an average of $1.61 with a low of $1.36 and a high of $2.30 and an implied 0% ROI. By 2030, the average price rises to $2.08 with a max of $3.27 and a 28.9% ROI, signaling a bullish tilt for the longer horizon.
Longer term projections extend to 2040 and 2050, with the average price expected at $5.24 in 2040 (min $2.85, max $9.96, ROI 225.3%) and $8.39 in 2050 (min $3.78, max $17.82, ROI 421.1%), both with bullish sentiment. Overall, the outlook suggests meaningful upside over the multi-year horizon, albeit with uncertainty inherent in price forecasts.
A major floor 27.7% below — a decisive break under it would weaken the trend.
The nearest floor, 10.8% below — buyers have tended to step in here.
The nearest ceiling, 19.9% above — a clean break opens room to run.
A major ceiling 51.2% above — clearing it would confirm fresh momentum.
Key CHRS support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CHRS market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.60 | Buy | $1.62 | Buy |
| MA 10 | $1.59 | Buy | $1.62 | Buy |
| MA 20 | $1.68 | Sell | $1.66 | Buy |
| MA 50 | $1.71 | Sell | $1.70 | Sell |
| MA 100 | $1.76 | Sell | $1.68 | Sell |
| MA 200 | $1.58 | Buy | $1.58 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 48.74 | Neutral |
| Stoch RSI (14) | 50.62 | Neutral |
| CCI (20) | -14.45 | Neutral |
| Williams %R (14) | -61.70 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -5.14 | Sell |
| Bollinger %B (20,2) | 0.45 | Neutral |
| Stochastic %K (14) | 38.30 | Neutral |
| TRIX (15) | -0.34 | Sell |
| Awesome (5,34) | -0.14 | Sell |
| Ultimate (7,14,28) | 56.99 | Neutral |
| Momentum (10) | -0.05 | Sell |
| Aroon Osc (25) | -24.00 | Sell |
| Hull MA (9) | 1.65 | Buy |
| ADX (14) | 11.38 | Neutral |
| ATR (14) | 0.05 | Info |
The near-term picture is neutral. The RSI(14) sits at 50, and the price sits around the SMA50 of $1.71 relative to the SMA200 of $1.57, indicating no strong directional bias.
Key near-term levels include a support at $1.48 and resistance at $1.99. The thirty-day trading range spans from $1.25 to $2.07, framing the immediate volatility and upside potential. Annualized volatility is high at 70%, underscoring substantial price variability in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.36 | $1.66 | $2.37 | 0% | Neutral | |
| $1.36 | $1.77 | $2.47 | +7% | Neutral | |
| $1.49 | $2.02 | $2.94 | +22% | Bullish | |
| $1.43 | $2.00 | $3.01 | +20% | Bullish | |
| $1.55 | $2.23 | $3.47 | +34% | Bullish | |
| $1.93 | $2.84 | $4.53 | +71% | Bullish | |
| $2.06 | $3.10 | $5.07 | +87% | Bullish | |
| $2.28 | $3.52 | $5.87 | +112% | Bullish | |
| $2.32 | $3.67 | $6.23 | +121% | Bullish | |
| $2.13 | $3.43 | $5.93 | +106% | Bullish | |
| $3.22 | $5.72 | $10.66 | +245% | Bullish | |
| $4.44 | $9.44 | $19.56 | +468% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $1.36 | $1.66 | $1.94 | +0.00% |
| June 2026 | $1.37 | $1.62 | $1.97 | -2.60% |
| July 2026 | $1.41 | $1.68 | $2.08 | +4.20% |
| August 2026 | $1.42 | $1.72 | $2.16 | +2.03% |
| September 2026 | $1.40 | $1.70 | $2.15 | -1.18% |
| October 2026 | $1.43 | $1.76 | $2.25 | +3.33% |
| November 2026 | $1.49 | $1.84 | $2.38 | +4.81% |
| December 2026 | $1.47 | $1.82 | $2.37 | -1.01% |
Click any year to see its month-by-month CHRS forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, CHRS could reach as high as $2.37, with a base case around $1.66 and support toward $1.36 — roughly 0% from $1.66. A consolidation phase looks the most probable path here.
Expect CHRS to range from $1.36 to $2.47 through 2027. The $1.77 average target implies a +7% move from current prices. That is up +7% on the projected 2026 average. Price action looks broadly range-bound.
The CHRS price prediction for 2028 points to an average of $2.02 (low $1.49, high $2.94) — a potential gain of +22% on today's $1.66. Buyers look set to stay in control over this stretch.
In 2029, CHRS is projected to trade between $1.43 and $3.01, averaging $2.00 — a potential gain of +20% from today's $1.66. That is -1% versus the projected 2028 average. Momentum favours further upside here.
Coherus Oncology, Inc.'s 2030 outlook centres on $2.23, within a $1.55 to $3.47 range. That is up +12% on the projected 2029 average. That marks a +34% change versus current levels. Buyers look set to stay in control over this stretch.
By 2031, CHRS could reach as high as $4.53, with a base case around $2.84 and support toward $1.93 — roughly +71% from $1.66. Momentum favours further upside here.
Expect CHRS to range from $2.06 to $5.07 through 2032. The $3.10 average target implies a +87% move from current prices. That is up +9% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The CHRS price prediction for 2033 points to an average of $3.52 (low $2.28, high $5.87) — a potential gain of +112% on today's $1.66. Momentum favours further upside here.
In 2034, CHRS is projected to trade between $2.32 and $6.23, averaging $3.67 — a potential gain of +121% from today's $1.66. That is up +4% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Coherus Oncology, Inc.'s 2035 outlook centres on $3.43, within a $2.13 to $5.93 range. That is -7% versus the projected 2034 average. That marks a +106% change versus current levels. Momentum favours further upside here.
By 2040, CHRS could reach as high as $10.66, with a base case around $5.72 and support toward $3.22 — roughly +245% from $1.66. Buyers look set to stay in control over this stretch.
Expect CHRS to range from $4.44 to $19.56 through 2050. The $9.44 average target implies a +468% move from current prices. That is up +65% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in CHRS today (≈ 602.409639 CHRS) could be worth
$5,684.33
+$4,684.33 (+468%) by 2050 · US Dollar
Based on the average projected CHRS price of $9.44 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CHRSwould be worth at today's price.
$1,000 invested in CHRS on May 27, 2025 (≈ 1,283.697073 CHRS) would be worth
$2,130.94
+$1,130.94 (+113.1%) today · 2.13× · US Dollar
Based on a CHRS entry price of $0.779 vs. today's $1.66.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.51 | $1,099.34 | +9.9% |
| 1 month ago | $1.84 | $902.17 | -9.8% |
| 3 months ago | $1.69 | $982.25 | -1.8% |
| 6 months ago | $1.36 | $1,220.59 | +22.1% |
| 1 year ago | $0.779 | $2,130.94 | +113.1% |
| All time (5.0y) ago | $13.47 | $123.24 | -87.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CHRS forecast.
Our base-case forecast reaches $3.30 around 2033.
Implied market cap at $3.30: $509.02M
The multi-year view shows a clear growth arc after a modest start in 2026–2029, where the forecasted averages are $1.61, $1.69, $1.93 and $1.86 respectively, with ROIs of 0%, 5.2%, 19.6% and 15.7% as sentiment remains NEUTRAL.
In 2030 the average forecast climbs to $2.08 with a max of $3.27 and a 28.9% ROI, accompanied by a BULLISH sentiment. The ascent continues through 2031–2034, with averages of $2.65, $2.88, $3.29 and $3.40 and ongoing bullish outlook across those years (2031: 64.8% ROI; 2032: 78.6%; 2033: 104.6%; 2034: 111.5%).
By 2040 the forecasted average reaches $5.24 (min $2.85, max $9.96, ROI 225.3%) and by 2050 it rises to $8.39 (min $3.78, max $17.82, ROI 421.1%), with sentiment remaining BULLISH. These figures illustrate a substantial long-run upside, while emphasizing that these are estimates and not guarantees.
Tap a question to reveal the answer.
In 2030 the forecasted average price is $2.08, with a low of $1.43 and a high of $3.27, and a 28.9% ROI. The sentiment is BULLISH.
The forecast shows a bullish trajectory from 2030 onward, with 2030 average around $2.08 and rising to $8.39 by 2050, with ROIs up to 421.1%. However, the early years show more modest gains and these are estimates, not guarantees.
Yes. The forecast max reaches $5.59 in 2033 and $5.89 in 2034, with a long-run max of $17.82 in 2050.
Current price is $1.61 and market cap is $248.34M. The rank is 3674.
For 2028, the average forecast price is $1.93, with a min of $1.41 and a max of $2.84, and a RO I of 19.6%. The sentiment is NEUTRAL.
Coherus Oncology, Inc. Community Discussion
0Share your Coherus Oncology, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.